托法替布、培非替尼、索西替尼、巴瑞替尼、阿布昔替尼和氘可来昔替尼治疗斑块状银屑病的疗效与安全性——一项网络Meta分析
本研究通过纳入8项随机对照试验共3612例中重度斑块状银屑病患者的网络Meta分析,比较托法替布、培非替尼、索西替尼、巴瑞替尼、阿布昔替尼和氘可来昔替尼的疗效与安全性,发现JAK抑制剂在8周和12周时PASI75应答均优于安慰剂,托法替布15mg每日两次的PASI75应答概率最高。
要点
- JAK抑制剂在8周和12周时PASI75应答均优于安慰剂。
- 托法替布15mg每日两次的PASI75应答概率最高(8周SUCRA=0.938,12周SUCRA=0.937)。
- 除氘可来昔替尼6mg每日两次和12mg每日一次外,其他JAK抑制剂安全性非劣于安慰剂。
核心结论
- JAK抑制剂对中重度斑块状银屑病具有有前景的治疗疗效。
- 托法替布在疗效和安全性上优于培非替尼、索西替尼、巴瑞替尼、阿布昔替尼和氘可来昔替尼。
研究设计与样本
- 网络Meta分析,纳入8项随机对照试验,共3612例中重度斑块状银屑病患者,涉及托法替布、培非替尼、索西替尼、巴瑞替尼、阿布昔替尼和氘可来昔替尼。
主要发现
- JAK抑制剂在8周和12周时PASI75应答均优于安慰剂。
- 托法替布15mg每日两次的PASI75应答概率最高(8周SUCRA=0.938,12周SUCRA=0.937),其次为托法替布10mg每日两次(8周SUCRA=0.905,12周SUCRA=0.908)和氘可来昔替尼12mg每日一次(8周SUCRA=0.874,12周SUCRA=0.837)。
- PGA应答观察到类似结果。
- 安全性评估显示,除氘可来昔替尼6mg每日两次和12mg每日一次外,所有JAK抑制剂安全性非劣于安慰剂。
- 安全性排名首位为托法替布2mg每日两次,其次为氘可来昔替尼3mg每日一次和托法替布5mg每日两次。
关键数值与推荐
- 疗效评估采用PASI75(较基线改善75%)和PGA应答比例。
- 安全性评估采用治疗相关不良事件发生率。
- 综合评估疗效和安全性,托法替布(2mg、5mg、10mg、15mg每日两次)优于其他纳入的JAK抑制剂,具有满意的PASI75和PGA应答以及相对较低的不良事件发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Janus kinase (JAK) inhibitors are novel treatment approaches for psoriasis. However, there is no direct comparison of JAK inhibitors in plaque psoriasis. In order to compare the efficacy and safety of JAK inhibitors in psoriasis, we conducted a network meta-analysis using eligible randomized clinical trials (RCTs). The efficacy of JAK inhibitors was evaluated using a 75% improvement in Psoriasis Area and Severity Index (PASI75) from baseline, and the proportion of patients achieving the Physician's Global Assessment (PGA) response. The incidence of treatment-related adverse events (AEs) was also assessed. A total of eight RCTs with tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib were included. A total of 3612 participants who were diagnosed with moderate-to-severe plaque psoriasis were analysed. Overall, JAK inhibitors showed superior PASI75 response over placebo at both 8 and 12 weeks. Among all included JAK inhibitors, tofacitinib 15 mg twice a day (BID) had the highest probability of achieving PASI75 at both 8 and 12 weeks (SUCRA = 0.938 and 0.937, separately), followed by tofacitinib 10 mg BID (SUCRA = 0.905 and 0.908, separately) and deucravacitinib 12 mg once daily (QD) (SUCRA = 0.874 and 0.837, separately). A similar finding was observed for PGA response. Safety assessment showed that all JAK inhibitors had non-inferior safety compared with placebo, except for deucravacitinib 6 mg BID and 12 mg QD. Tofacitinib 2 mg BID was the first-ranked drug for safety profile followed by deucravacitinib 3 mg QD, and tofacitinib 5 mg BID. When comprehensively evaluated the efficacy and safety, tofacitinib (2 mg, 5 mg, 10 mg, 15 mg BID) was superior to other included JAK inhibitors with satisfying PASI75 and PGA response, as well as relatively low incidence of AEs. Our study confirmed that JAK inhibitors had promising treatment efficacy for moderate-to-severe plaque psoriasis. Tofacitinib showed superior efficacy and safety over peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib.
引用
- Zhang L, Guo L, Wang L, et al. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis. J Eur Acad Dermatol Venereol. 2022. PMID: 35608188. doi:10.1111/jdv.18263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。